Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE

Bone turnover markers after the menopause: T-score approach

(2018) Fatma Gossiel et al.   BONE

Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study

(2018) M. A. Paggiosi et al.   OSTEOPOROSIS INTERNATIONAL

Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling

(2016) Gary Hattersley et al.   ENDOCRINOLOGY

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis

(2016) Paul D. Miller et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PINP as an aid for monitoring patients treated with teriparatide

(2010) Mika Tsujimoto et al.   BONE

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide

(2010) A. Blumsohn et al.   OSTEOPOROSIS INTERNATIONAL

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

(2010) S. Vasikaran et al.   OSTEOPOROSIS INTERNATIONAL

Rapid and robust response of biochemical markers of bone formation to teriparatide therapy

(2009) Sarah J. Glover et al.   BONE